Liberty Leaf - Wo Rauch ist, ist doch auch... - 500 Beiträge pro Seite
eröffnet am 17.06.20 21:34:41 von
neuester Beitrag 20.01.21 08:31:00 von
neuester Beitrag 20.01.21 08:31:00 von
Beiträge: 20
ID: 1.326.435
ID: 1.326.435
Aufrufe heute: 0
Gesamt: 778
Gesamt: 778
Aktive User: 0
ISIN: CA66980V1067 · WKN: A2P7XA
0,0130
EUR
+13,04 %
+0,0015 EUR
Letzter Kurs 11:42:27 Lang & Schwarz
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6,0000 | +25,00 | |
| 9,2900 | +20,96 | |
| 111,75 | +18,87 | |
| 0,6400 | +18,52 | |
| 1,8700 | +18,35 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 9,7200 | -19,60 | |
| 0,9250 | -23,55 | |
| 20,000 | -28,06 | |
| 14,510 | -32,32 | |
| 8,0000 | -36,76 |
Feedback
Das ist doch etwas im Busch!
Antwort auf Beitrag Nr.: 64.053.057 von Boerseninsider-com am 17.06.20 21:34:41Aufwärtstrend sieht spannend aus - Wäre nicht überrascht, wenn die Aktie in den nächsten Wochen weiter nach oben will.
Spannende Ausgangslage
Spannende Ausgangslage
Die Rauchzeichen waren da. Nur wenige haben es gesehen!
Liberty Leaf to Acquire Nova Mentis Biotech Corp. - Liberty Leaf Augments Portfolio with Entrance into the Emerging Psilocybin Therapy Market
VANCOUVER, BC, June 22, 2020 /CNW/ - Liberty Leaf Holdings Ltd. (CSE: LIB) (FSE: HN3P) (OTCPK: LIBFF) ("LIB" or the "Company") is pleased to announce that it has entered into an agreement (the "Agreement") with Nova Mentis Biotech Corp. ("NOVA"), pursuant to which LIB will acquire, by way of share exchange, 100 per cent of all of the issued and outstanding securities of NOVA (the "Transaction").
Liberty Leaf Logo (CNW Group/Liberty Leaf Holdings)
Highlights of the Transaction:
LIB gains NOVA's current net cash balance of approximately $1.2M CDN;
Adds synergistic accompaniment to LIB's operating and licensed cannabis assets within the health and wellness sector;
Bolsters roster of personnel who possess experience within scientific and R&D community; and
Provides opportunity for intellectual property creation as NOVA advances its research mandate.
NOVA is a research and development driven company that is focused on investigating the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes. NOVA is of the view that its target indications represent vast and growing segments of the population. For example, in the United States, more than 10.5% of the population has Diabetes, which represents approximately 34.2 million people. Diabetes treatment can bare significant economic burden to patients with the average out of pocket monthly cost being estimated at $360 USD. According to a report by Fortune Business Insights, the global diabetes drug market size was valued at USD $48 Billion in 2018 and is projected to reach USD $78 Billion by 2026. Increasing societal prevalence of sedentary lifestyles coupled with vast access to inexpensive and nutritionally void food options are likely to contribute to further incidence of obesity and diabetes in the future. According to the National Center for Health Statistics, 39.8% of the US population aged 20 and over were considered obese in 2016, with an additional 31.8% being considered overweight. Obese individuals have a significantly higher incidence of depression (close to 30%) compared to the general population. Bidirectionally, according to the CDC, about 43% of depressed people are obese.
The strong therapeutic potential of psilocybin has emerged for a wide range of disorders, primarily mental health related. NOVA is focusing on a cohort group that has been very difficult to treat, both acutely and also in a sustainable way. This group of individuals have an overlap in two widespread and very important indications, obesity and depression. These comorbid conditions share inflammation as an important common mediator. NOVA's pre-clinical scientific study thus far is focused on targeting the gut-brain axis to modulate inflammation in this context. The aim is to utilize the unique properties of psilocybin to address both physiological and behavioural factors in obesity and comorbid depression.
NOVA was founded and is led by Dr. Aylia Mohammadi. Dr. Mohammadi obtained her PhD in Biological Physics from the Donnelly Centre for Cellular & Biomolecular Research at the University of Toronto, and subsequently completed a postdoctoral fellowship at the Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital in Toronto. Aylia is a TEDx speaker, and has presented her work at international conferences. Her graduate training was inherently multidisciplinary, integrating techniques in molecular biology, neuroscience, and genetics. For her postdoctoral research, she examined underlying molecular mechanisms of inflammatory bowel disease, giving her a strong and relevant background to guide NOVA's scientific aims.
"Recent scientific advancement coupled with shifting opinions amongst, both the medical and general communities, at large regarding psychedelics including psilocybin make it a sector worthy of investment," stated Will Rascan, President and CEO of LIB. "Since our shift into cannabis in 2014, and our subsequent investment in Just Kush Enterprises Ltd, - now a holder of three Health Canada Cannabis Licenses – we have focused on emerging trends and shifting public awareness of natural based compounds for health and wellness, I believe this acquisition compliments our current legal cannabis portfolio and provides stakeholders with an early entrance in a new flourishing market."
Transaction
Pursuant to the Agreement, LIB will acquire 100 per cent of the issued and outstanding shares in the capital of NOVA in exchange for 115,000,000 common shares in the capital of the Company (the "LIB Consideration Shares") at a deemed price per share equal to $0.05.
In connection with the Transaction, certain NOVA shareholders have agreed to a voluntary hold period pursuant to which 43,907,695 LIB Consideration Shares will be subject to trading restriction. Specifically, 21,953,847 LIB Consideration Shares will be released on the three (3) month anniversary of closing the Transaction, and 21,953,848 LIB Consideration Shares will be released on the six (6) month anniversary of closing the Transaction.
Consolidation
LIB also announces that it plans to consolidate all of the Company's issued and outstanding common shares on the basis of four (4) pre-consolidated shares for every one (1) post-consolidated share (the "Consolidation"). After giving effect to the Transaction, LIB will have 243,526,132 common shares issued and outstanding. Upon completion of the Consolidation, LIB will have 60,881,533 common shares issued and outstanding. Further, in connection with the Consolidation, the Company intends to change its name to "Nova Mentis Life Science Corp." with a corresponding symbol change to "NOVA".
The Company will issue a further news release announcing the effective date in which the Company will commence trading under the new name and symbol on a post-consolidated basis.
About Liberty Leaf Holdings Ltd.
Liberty Leaf Holdings Ltd. is a Canadian-based, public company whose focus is to build and support a diversified portfolio of cannabis-sector businesses, including cultivation, processing and value-added products within this dynamic and fast-growing sector.
On Behalf of the Board
Will Rascan, President & CEO
Liberty Leaf Holdings Ltd.
Phone: 778-819-0244
Toll Free: 1-833-LIB-LEAF (542-5323)
Twitter: @LibertyLeafCSE
Facebook: LibertyLeafCSE
Instagram: libertyleafcse
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Liberty Leaf's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.
SOURCE Liberty Leaf Holdings
Liberty Leaf to Acquire Nova Mentis Biotech Corp. - Liberty Leaf Augments Portfolio with Entrance into the Emerging Psilocybin Therapy Market
VANCOUVER, BC, June 22, 2020 /CNW/ - Liberty Leaf Holdings Ltd. (CSE: LIB) (FSE: HN3P) (OTCPK: LIBFF) ("LIB" or the "Company") is pleased to announce that it has entered into an agreement (the "Agreement") with Nova Mentis Biotech Corp. ("NOVA"), pursuant to which LIB will acquire, by way of share exchange, 100 per cent of all of the issued and outstanding securities of NOVA (the "Transaction").
Liberty Leaf Logo (CNW Group/Liberty Leaf Holdings)
Highlights of the Transaction:
LIB gains NOVA's current net cash balance of approximately $1.2M CDN;
Adds synergistic accompaniment to LIB's operating and licensed cannabis assets within the health and wellness sector;
Bolsters roster of personnel who possess experience within scientific and R&D community; and
Provides opportunity for intellectual property creation as NOVA advances its research mandate.
NOVA is a research and development driven company that is focused on investigating the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes. NOVA is of the view that its target indications represent vast and growing segments of the population. For example, in the United States, more than 10.5% of the population has Diabetes, which represents approximately 34.2 million people. Diabetes treatment can bare significant economic burden to patients with the average out of pocket monthly cost being estimated at $360 USD. According to a report by Fortune Business Insights, the global diabetes drug market size was valued at USD $48 Billion in 2018 and is projected to reach USD $78 Billion by 2026. Increasing societal prevalence of sedentary lifestyles coupled with vast access to inexpensive and nutritionally void food options are likely to contribute to further incidence of obesity and diabetes in the future. According to the National Center for Health Statistics, 39.8% of the US population aged 20 and over were considered obese in 2016, with an additional 31.8% being considered overweight. Obese individuals have a significantly higher incidence of depression (close to 30%) compared to the general population. Bidirectionally, according to the CDC, about 43% of depressed people are obese.
The strong therapeutic potential of psilocybin has emerged for a wide range of disorders, primarily mental health related. NOVA is focusing on a cohort group that has been very difficult to treat, both acutely and also in a sustainable way. This group of individuals have an overlap in two widespread and very important indications, obesity and depression. These comorbid conditions share inflammation as an important common mediator. NOVA's pre-clinical scientific study thus far is focused on targeting the gut-brain axis to modulate inflammation in this context. The aim is to utilize the unique properties of psilocybin to address both physiological and behavioural factors in obesity and comorbid depression.
NOVA was founded and is led by Dr. Aylia Mohammadi. Dr. Mohammadi obtained her PhD in Biological Physics from the Donnelly Centre for Cellular & Biomolecular Research at the University of Toronto, and subsequently completed a postdoctoral fellowship at the Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital in Toronto. Aylia is a TEDx speaker, and has presented her work at international conferences. Her graduate training was inherently multidisciplinary, integrating techniques in molecular biology, neuroscience, and genetics. For her postdoctoral research, she examined underlying molecular mechanisms of inflammatory bowel disease, giving her a strong and relevant background to guide NOVA's scientific aims.
"Recent scientific advancement coupled with shifting opinions amongst, both the medical and general communities, at large regarding psychedelics including psilocybin make it a sector worthy of investment," stated Will Rascan, President and CEO of LIB. "Since our shift into cannabis in 2014, and our subsequent investment in Just Kush Enterprises Ltd, - now a holder of three Health Canada Cannabis Licenses – we have focused on emerging trends and shifting public awareness of natural based compounds for health and wellness, I believe this acquisition compliments our current legal cannabis portfolio and provides stakeholders with an early entrance in a new flourishing market."
Transaction
Pursuant to the Agreement, LIB will acquire 100 per cent of the issued and outstanding shares in the capital of NOVA in exchange for 115,000,000 common shares in the capital of the Company (the "LIB Consideration Shares") at a deemed price per share equal to $0.05.
In connection with the Transaction, certain NOVA shareholders have agreed to a voluntary hold period pursuant to which 43,907,695 LIB Consideration Shares will be subject to trading restriction. Specifically, 21,953,847 LIB Consideration Shares will be released on the three (3) month anniversary of closing the Transaction, and 21,953,848 LIB Consideration Shares will be released on the six (6) month anniversary of closing the Transaction.
Consolidation
LIB also announces that it plans to consolidate all of the Company's issued and outstanding common shares on the basis of four (4) pre-consolidated shares for every one (1) post-consolidated share (the "Consolidation"). After giving effect to the Transaction, LIB will have 243,526,132 common shares issued and outstanding. Upon completion of the Consolidation, LIB will have 60,881,533 common shares issued and outstanding. Further, in connection with the Consolidation, the Company intends to change its name to "Nova Mentis Life Science Corp." with a corresponding symbol change to "NOVA".
The Company will issue a further news release announcing the effective date in which the Company will commence trading under the new name and symbol on a post-consolidated basis.
About Liberty Leaf Holdings Ltd.
Liberty Leaf Holdings Ltd. is a Canadian-based, public company whose focus is to build and support a diversified portfolio of cannabis-sector businesses, including cultivation, processing and value-added products within this dynamic and fast-growing sector.
On Behalf of the Board
Will Rascan, President & CEO
Liberty Leaf Holdings Ltd.
Phone: 778-819-0244
Toll Free: 1-833-LIB-LEAF (542-5323)
Twitter: @LibertyLeafCSE
Facebook: LibertyLeafCSE
Instagram: libertyleafcse
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Liberty Leaf's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.
SOURCE Liberty Leaf Holdings
Antwort auf Beitrag Nr.: 64.122.301 von Boerseninsider-com am 22.06.20 10:23:46Danke für die News
Hört sich interessant an. Bin sehr neugierig auf die Entwicklung in den nächsten Wochen
Hört sich interessant an. Bin sehr neugierig auf die Entwicklung in den nächsten Wochen
Sprunghafter Anstieg der Handelsvolumen heute!
Trading Spotlight
gibt aber einen 1 zu 4 reverse split
Mushroom Index Investor Team
Deutsche Website:https://mushroomstockindex.com/de/
Liberty Leaf Holdings (CSE:LIB) trading at 0.07 cents, announced today they are making the transition to psilocybin, by acquiring Nova Mentis Biotech Corp (NOVA), who together will focus on psilocybin research for the potential treatment of diabetes and obesity in relation to depression.
Depression is often coupled with metabolic indications as a comorbidity, as 43% of depressed people are categorized as obese. NOVA is exploring the possibility that psilocybin can not only help with mental health of individuals, but also aid in the physical health of people suffering from obesity and diabetes. While other psilocybin research has largely focused on the brain’s serotonin receptors interacting with the psychedelic compound, NOVA’s research focuses on the serotonin receptors in the gut, and their communication pathways with the brain.
We will be initiating coverage on this story today. A representative of the Mushroom Stock Index will be speaking with Dr. Aylia Mohammadi of NOVA, who has a PhD in Biological Physics, to better understand NOVA’s unique approach to understanding the effects of psilocybin. We will report on our discussion as soon as possible for our readers.
Liberty Leaf is worth roughly $17-18 million after this transaction, adding $1.2 million CAD to its treasury. Note that most recently, Compass Pathways, who focuses on psilocybin as a method of treating depression, raised $80 million at an $800 million valuation. Clearly, there should be some short-term upside on LIB entering this space.
Good fortune to all subscribers,
James Harris
Antwort auf Beitrag Nr.: 64.130.923 von ThatstheWayItGoes am 22.06.20 18:25:29Ich befürworte den Aktiensplit!
Antwort auf Beitrag Nr.: 64.130.998 von Boerseninsider-com am 22.06.20 18:30:35meistens fällt der Kurs nach einem reverse split wieder
Antwort auf Beitrag Nr.: 64.131.028 von ThatstheWayItGoes am 22.06.20 18:34:05
Ich glaube hier wir das nicht der Fall sein. Aber ich habe mir erst 3/4 meiner Position in Liberty Leaf gekauft. Sollte der Aktienkurs etwas zurückkommen, werde ich nochmals nachkaufen.
Zitat von ThatstheWayItGoes: meistens fällt der Kurs nach einem reverse split wieder
Ich glaube hier wir das nicht der Fall sein. Aber ich habe mir erst 3/4 meiner Position in Liberty Leaf gekauft. Sollte der Aktienkurs etwas zurückkommen, werde ich nochmals nachkaufen.
Antwort auf Beitrag Nr.: 64.131.253 von Boerseninsider-com am 22.06.20 18:48:01ja, ich bin auch optimistisch hier, wir werden sehen
Antwort auf Beitrag Nr.: 64.131.253 von Boerseninsider-com am 22.06.20 18:48:01Habe das Gewehr ebenfalls im Anschlag
Denke, heute ist ein guter Kauftag
(keine Kauf oder Verkauf Empfehlung)
Denke, heute ist ein guter Kauftag
(keine Kauf oder Verkauf Empfehlung)
Digging into $LIB's acquisition of Nova Mentis with Dr. Aylia Mohammadi
When deciding whether to invest in a junior stock or not, the first box to check is whether you have faith in management to execute their vision. Psychedelic medicine is a new, burgeoning sector, and having experienced, capable scientists on your team is a necessity. On June 22nd, Liberty Leaf (CSE:LIB) acquired Nova Mentis, a research company, spearheaded by Dr. Aylia Mohammadi, who has a PhD in Biological Physics. Today we spent two hours with Dr. Mohammadi, discussing the company’s aggressive plan to prove her hypothesis that the benefits of psilocybin do not just relate to mental health, but also, to the well-being of the body.
Why Nova Mentis is Different from the Rest
If you’ve read our previous articles, you’re likely aware that psilocybin was granted breakthrough status by the FDA in November, 2019, to fast-track tests for treatment of depression related mental health issues. In our Psilocybin Drug Profile , we noted how serotonin receptors in the brain worked to induce central nervous system effects on the body, however, the compound also interacts with serotonin receptors in the gut. To our knowledge, the vast majority of psilocybin research has been focused on the brain, but Dr. Mohammadi is taking a new approach, measuring the effects of psilocybin in the gut and the gut-brain axis . Ideally, through her research, Dr. Mohammadi intends to explore the anti-inflammatory effects of psilocybin to therapeutically target depression in individuals with comorbid obesity and diabetes.
A 2008 study published in the Journal of Pharmacology and Experimental Therapeutics demonstrated that the activation of the 5-HT(2A) serotonin receptor, which is one target of psychedelics such as psilocybin, produces a potent anti-inflammatory effect. This receptor behaves differently depending on where it is and what is attached, and to date has been studied primarily for its role in the brain. However this receptor is expressed in many tissues, including the gut. There are direct and indirect pathways of communication between the gut and the brain. The Vagus nerve, for example, connects the gut to the brain, working in both directions, sending messages, and receiving them. One research aim at Nova Mentis is to understand the therapeutic potential of activating these and other receptors with psilocybin in the “second brain” that lives in the gut, our enteric nervous system.
There is a reciprocal relationship between depression and obesity, since having one increases the risk of having the other. They often appear together as comorbidities. In the United States, 43% of depressed people are labelled as obese, while 30% of obese individuals experience depression. 27% of Canadians are labelled as obese, and 36% are considered overweight, based on BMI stats. Half of Canadians will experience at least one mental health related episode by the age of 40. Depending on the person, depression can change one’s appetite – some people eat less, and some eat more. The pro-inflammatory state may contribute to overeating while also driving insulin resistance. Psilocybin has therapeutic potential in a disease model that combines treatment of physiological issues with behavioural change. In addition to the anti-inflammatory qualities, anecdotal evidence of subjects taking various doses of psilocybin often report a lack of appetite. Therefore, micro-dosing psilocybin might not only solve depression related issues, but could also aid in the comorbidity issues of metabolic disorders.
Initial Test Plans
Each company’s research must be specific towards establishing a clear thesis, in order to prove a new drug’s efficacy, and save time bringing a new drug to market. Nova Mentis plans to run two concurrent tests, with the first preclinical experiments scheduled to take 3-5 months, aimed at determining the systemic anti-inflammatory effect of psilocybin with obesity and while measuring microbiome. The tests will aim to understand how psilocybin modulates the gut-brain axis and effects on metabolic and mental health. Dr. Mohammadi also will explore subjects of chronic low-grade inflammation, or systemic inflammation, investigating alterations in the microbiome and intestinal barrier function.
Final Thoughts
Throughout our conversation, Dr. Mohammadi’s passion and enthusiasm about her research was infectious and her objective moving forward is clear. The potential market for psilocybin might grow exponentially as a result of Mohammadi’s research to include a new segment for psilocybin therapy. If successful, Mohammadi’s research could prove the merits of microdosing psilocybin in appetite regulation, without hallucinogenic effects, while also solving mood altering effects through alterations in the microbiome.
We should also tell you, Dr. Mohammadi did mention the potential for her research to improve the psilocybin molecule for the purpose of improving the microdose outcome but she would not elaborate on this subject. If Mohammadi were able to achieve this feat, and her research proved her hypothesis, in 3-5 years, Liberty Leaf’s acquisition of Nova Mentis today on June 22nd will look like a genius move. For full disclosure, today we bought $LIB stock today, after our discussion with the doctor, and we look forward to bringing our readers future updates on her progress.
Stock Action
After Liberty Leaf’s announcement of the psilocybin deal, $LIB traded ten times its normal daily volume, and it seems many of the weak hands in the stock were shaken out into stronger hands, with smart money accumulating. We expect this trend to continue as the company begins to talk about its new future, and investors learn what we learned today. It is also important to note that it appears Nova Mentis will not face the same issue as Champignon’s failure to publish a Business Acquisition Report (BAR) as there were $6,584,935 in assets as of the last audited financials, so the acquisition would not exceed the asset threshold requirement.
Good fortune to all subscribers,
James
www.mushroomstockindex.com
Mushroom Index Investor Team
86 Mining Services Inc, Torre A, Suite 1002, Torre De Las Americas,
When deciding whether to invest in a junior stock or not, the first box to check is whether you have faith in management to execute their vision. Psychedelic medicine is a new, burgeoning sector, and having experienced, capable scientists on your team is a necessity. On June 22nd, Liberty Leaf (CSE:LIB) acquired Nova Mentis, a research company, spearheaded by Dr. Aylia Mohammadi, who has a PhD in Biological Physics. Today we spent two hours with Dr. Mohammadi, discussing the company’s aggressive plan to prove her hypothesis that the benefits of psilocybin do not just relate to mental health, but also, to the well-being of the body.
Why Nova Mentis is Different from the Rest
If you’ve read our previous articles, you’re likely aware that psilocybin was granted breakthrough status by the FDA in November, 2019, to fast-track tests for treatment of depression related mental health issues. In our Psilocybin Drug Profile , we noted how serotonin receptors in the brain worked to induce central nervous system effects on the body, however, the compound also interacts with serotonin receptors in the gut. To our knowledge, the vast majority of psilocybin research has been focused on the brain, but Dr. Mohammadi is taking a new approach, measuring the effects of psilocybin in the gut and the gut-brain axis . Ideally, through her research, Dr. Mohammadi intends to explore the anti-inflammatory effects of psilocybin to therapeutically target depression in individuals with comorbid obesity and diabetes.
A 2008 study published in the Journal of Pharmacology and Experimental Therapeutics demonstrated that the activation of the 5-HT(2A) serotonin receptor, which is one target of psychedelics such as psilocybin, produces a potent anti-inflammatory effect. This receptor behaves differently depending on where it is and what is attached, and to date has been studied primarily for its role in the brain. However this receptor is expressed in many tissues, including the gut. There are direct and indirect pathways of communication between the gut and the brain. The Vagus nerve, for example, connects the gut to the brain, working in both directions, sending messages, and receiving them. One research aim at Nova Mentis is to understand the therapeutic potential of activating these and other receptors with psilocybin in the “second brain” that lives in the gut, our enteric nervous system.
There is a reciprocal relationship between depression and obesity, since having one increases the risk of having the other. They often appear together as comorbidities. In the United States, 43% of depressed people are labelled as obese, while 30% of obese individuals experience depression. 27% of Canadians are labelled as obese, and 36% are considered overweight, based on BMI stats. Half of Canadians will experience at least one mental health related episode by the age of 40. Depending on the person, depression can change one’s appetite – some people eat less, and some eat more. The pro-inflammatory state may contribute to overeating while also driving insulin resistance. Psilocybin has therapeutic potential in a disease model that combines treatment of physiological issues with behavioural change. In addition to the anti-inflammatory qualities, anecdotal evidence of subjects taking various doses of psilocybin often report a lack of appetite. Therefore, micro-dosing psilocybin might not only solve depression related issues, but could also aid in the comorbidity issues of metabolic disorders.
Initial Test Plans
Each company’s research must be specific towards establishing a clear thesis, in order to prove a new drug’s efficacy, and save time bringing a new drug to market. Nova Mentis plans to run two concurrent tests, with the first preclinical experiments scheduled to take 3-5 months, aimed at determining the systemic anti-inflammatory effect of psilocybin with obesity and while measuring microbiome. The tests will aim to understand how psilocybin modulates the gut-brain axis and effects on metabolic and mental health. Dr. Mohammadi also will explore subjects of chronic low-grade inflammation, or systemic inflammation, investigating alterations in the microbiome and intestinal barrier function.
Final Thoughts
Throughout our conversation, Dr. Mohammadi’s passion and enthusiasm about her research was infectious and her objective moving forward is clear. The potential market for psilocybin might grow exponentially as a result of Mohammadi’s research to include a new segment for psilocybin therapy. If successful, Mohammadi’s research could prove the merits of microdosing psilocybin in appetite regulation, without hallucinogenic effects, while also solving mood altering effects through alterations in the microbiome.
We should also tell you, Dr. Mohammadi did mention the potential for her research to improve the psilocybin molecule for the purpose of improving the microdose outcome but she would not elaborate on this subject. If Mohammadi were able to achieve this feat, and her research proved her hypothesis, in 3-5 years, Liberty Leaf’s acquisition of Nova Mentis today on June 22nd will look like a genius move. For full disclosure, today we bought $LIB stock today, after our discussion with the doctor, and we look forward to bringing our readers future updates on her progress.
Stock Action
After Liberty Leaf’s announcement of the psilocybin deal, $LIB traded ten times its normal daily volume, and it seems many of the weak hands in the stock were shaken out into stronger hands, with smart money accumulating. We expect this trend to continue as the company begins to talk about its new future, and investors learn what we learned today. It is also important to note that it appears Nova Mentis will not face the same issue as Champignon’s failure to publish a Business Acquisition Report (BAR) as there were $6,584,935 in assets as of the last audited financials, so the acquisition would not exceed the asset threshold requirement.
Good fortune to all subscribers,
James
www.mushroomstockindex.com
Mushroom Index Investor Team
86 Mining Services Inc, Torre A, Suite 1002, Torre De Las Americas,
Antwort auf Beitrag Nr.: 64.145.506 von Boerseninsider-com am 23.06.20 16:06:40Ein sehr interessanter Artikel!
Besten Dank für die Information
Besten Dank für die Information
Antwort auf Beitrag Nr.: 64.155.121 von Aktien-Fan am 24.06.20 09:49:19Sieht in meinen Augen so aus, dass wieder Bewegung nach oben einsetzt.
Wäre nicht überrascht, wenn die Aktie bis Ende Jahr weiter Richtung Can 0.40 marschiert
Wäre nicht überrascht, wenn die Aktie bis Ende Jahr weiter Richtung Can 0.40 marschiert
Mir gefällt die zuletzt getätigte Übernahme von Nova. Ich habe in den letzten Wochen in Kanada Stücke eingesammelt.
Ich bin gespannt wie sich die Aktie weiterentwickelt.
Ich bin gespannt wie sich die Aktie weiterentwickelt.
Antwort auf Beitrag Nr.: 65.902.647 von boersenreportpunktcom am 01.12.20 11:39:49Erachte ich auch so. Die Übernahme macht in meinen Augen Sinn.
Gerade im Gesundheitswesen bestehen wohl sehr grosse Chancen
Gerade im Gesundheitswesen bestehen wohl sehr grosse Chancen
Nova Mentis Appoints Dr. Marvin S. Hausman as Chairman of Scientific Advisory Board
Canada NewsWire
VANCOUVER, BC, Dec. 3, 2020
VANCOUVER, BC, Dec. 3, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce that it has appointed Dr. Marvin S. Hausman, MD as Chairman of its Scientific Advisory Board, effective immediately. Dr. Hausman is the Chief Medical Officer of Pilz Bioscience Corp., a wholly-owned subsidiary of NOVA and is leading their research and development efforts in medicinal psychedelics. Dr. Hausman is an immunologist and board-certified urological surgeon with more than 30 years of drug research and development experience with various pharmaceutical companies, including Bristol-Myers International, Mead-Johnson Pharmaceutical Co., E.R. Squibb, Medco Research and Axonyx.
Dr. Hausman's plan is to assemble an Advisory Board composed of scientific thought leaders who can help advance the newly emerging field of psilocybin therapeutics.
"I want to have a visibly active Scientific Advisory Board whose scientific knowledge is complementary, creative and furthers the development of our psychedelic medicines portfolio," says Dr. Hausman.
"Following our acquisition of Pilz Bioscience, the Board is privileged to have Dr. Hausman Chair the Scientific Advisory Board and provide guidance as we develop and advance our portfolio within the medicinal psychedelic sector," says Will Rascan, NOVA's President and CEO. "Given his successful career as a surgeon and biotech business leader, with expertise in drug commercialization, Dr. Hausman brings an impressive resume of success and a wealth of experience and passion to the NOVA team. We are excited and gratified to be working with him on our new journey."
Pursuant to a consulting agreement with Dr. Hausman, the Company has issued Dr. Hausman 250,000 common shares. The shares are subject to a hold period of four months and one day.
About Nova Mentis Life Science Corp.
Nova Mentis Life Science Corp. (formerly Liberty Leaf Holdings Ltd.) is a Canadian-based, public company whose focus is to build and support a diversified portfolio of health and wellness businesses. Key holdings include its wholly-owned subsidiary, Pilz Bioscience Corp., a biotechnology company developing medicinal psychedelics for neuroinflammatory conditions with a significant cognitive component and high unmet therapeutic needs, initially focussed on Autism Spectrum Disorder (ASD). - Nova Mentis Biotech Corp., a R&D driven company focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes – Just Kush Enterprises, an Okanagan BC based, Health Canada Standard Licensed facility focused on the cultivation of premium, small batch Kush dominant cultivars.
On Behalf of the Board
Will Rascan, President & CEO
Nova Mentis Life Science Corp.
Phone: 778-819-0244
Toll Free: 1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.
SOURCE Nova Mentis Life Science Corp.
View original content: http://www.newswire.ca/en/releases/archive/December2020/03/c…
Canada NewsWire
VANCOUVER, BC, Dec. 3, 2020
VANCOUVER, BC, Dec. 3, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce that it has appointed Dr. Marvin S. Hausman, MD as Chairman of its Scientific Advisory Board, effective immediately. Dr. Hausman is the Chief Medical Officer of Pilz Bioscience Corp., a wholly-owned subsidiary of NOVA and is leading their research and development efforts in medicinal psychedelics. Dr. Hausman is an immunologist and board-certified urological surgeon with more than 30 years of drug research and development experience with various pharmaceutical companies, including Bristol-Myers International, Mead-Johnson Pharmaceutical Co., E.R. Squibb, Medco Research and Axonyx.
Dr. Hausman's plan is to assemble an Advisory Board composed of scientific thought leaders who can help advance the newly emerging field of psilocybin therapeutics.
"I want to have a visibly active Scientific Advisory Board whose scientific knowledge is complementary, creative and furthers the development of our psychedelic medicines portfolio," says Dr. Hausman.
"Following our acquisition of Pilz Bioscience, the Board is privileged to have Dr. Hausman Chair the Scientific Advisory Board and provide guidance as we develop and advance our portfolio within the medicinal psychedelic sector," says Will Rascan, NOVA's President and CEO. "Given his successful career as a surgeon and biotech business leader, with expertise in drug commercialization, Dr. Hausman brings an impressive resume of success and a wealth of experience and passion to the NOVA team. We are excited and gratified to be working with him on our new journey."
Pursuant to a consulting agreement with Dr. Hausman, the Company has issued Dr. Hausman 250,000 common shares. The shares are subject to a hold period of four months and one day.
About Nova Mentis Life Science Corp.
Nova Mentis Life Science Corp. (formerly Liberty Leaf Holdings Ltd.) is a Canadian-based, public company whose focus is to build and support a diversified portfolio of health and wellness businesses. Key holdings include its wholly-owned subsidiary, Pilz Bioscience Corp., a biotechnology company developing medicinal psychedelics for neuroinflammatory conditions with a significant cognitive component and high unmet therapeutic needs, initially focussed on Autism Spectrum Disorder (ASD). - Nova Mentis Biotech Corp., a R&D driven company focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes – Just Kush Enterprises, an Okanagan BC based, Health Canada Standard Licensed facility focused on the cultivation of premium, small batch Kush dominant cultivars.
On Behalf of the Board
Will Rascan, President & CEO
Nova Mentis Life Science Corp.
Phone: 778-819-0244
Toll Free: 1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.
SOURCE Nova Mentis Life Science Corp.
View original content: http://www.newswire.ca/en/releases/archive/December2020/03/c…
auf watchlist
Tageschart mit bewegung...
Tageschart mit bewegung...
Antwort auf Beitrag Nr.: 66.394.382 von eula am 12.01.21 09:56:43scheint auch ne neue website zu geben
http://www.novamentis.ca/
http://www.novamentis.ca/
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,06 | |
| -0,34 | |
| -0,83 | |
| -0,45 | |
| -1,05 | |
| +0,12 | |
| +0,15 | |
| +6,80 | |
| 0,00 | |
| -8,00 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 224 | ||
| 136 | ||
| 117 | ||
| 76 | ||
| 43 | ||
| 37 | ||
| 37 | ||
| 34 | ||
| 31 | ||
| 30 |
Liberty Leaf - Wo Rauch ist, ist doch auch...
